Ainos (AIMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for November 7, 2025, with record date set as September 17, 2025.
Key proposals include election of directors, ratification of auditor, approval of special stock awards, and potential adjournment authorization.
Shareholders can vote by internet, phone, or mail, and may revoke proxies before the meeting.
Proxy materials and annual report are available online.
Voting matters and shareholder proposals
Election of seven directors, all current board members, for one-year terms.
Ratification of YCM CPA INC. as independent auditor for fiscal year ending December 31, 2024.
Approval to reserve up to 950,000 shares as special stock awards, not under the 2023 Stock Incentive Plan.
Authorization to adjourn the meeting if more time is needed to solicit proxies.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of seven members, with three qualifying as independent under SEC and Nasdaq rules.
Audit and Compensation Committees are fully independent and have defined charters.
Directors receive cash compensation and RSUs, with vesting schedules and annual retainers.
Code of business conduct and ethics applies to all directors, officers, and employees.
Directors and officers are indemnified and covered by insurance.
Latest events from Ainos
- AI Nose is scaling as an AI perception platform, targeting industrial and robotics growth in 2026.AIMD
Fireside chat2 Feb 2026 - Secondary offering of 6.7M shares enables liquidity for stockholders, no proceeds to company.AIMD
Registration Filing16 Dec 2025 - Registration enables resale of 6.7M+ shares from various agreements and awards.AIMD
Registration Filing16 Dec 2025 - Shareholders will vote on auditor ratification, special stock awards, and meeting adjournment.AIMD
Proxy Filing2 Dec 2025 - Votes sought for auditor ratification and 2 million special stock awards at September 2024 meeting.AIMD
Proxy Filing2 Dec 2025 - AI Nose commercialization and cost reductions narrowed Q3 2025 net loss as revenue grew.AIMD
Q3 202513 Nov 2025 - AI Nose rollout drove first revenues, a $2.1M order, and positive gross margin despite wider losses.AIMD
Q2 202513 Aug 2025 - Q2 net loss rose to $3.2M as revenue dropped to zero and drug development accelerated.AIMD
Q2 202413 Jun 2025 - Q3 net loss rose 24% to $3.7M as Ainos pivots from COVID-19 kits to new clinical products.AIMD
Q3 202413 Jun 2025